Compare McKesson Corporation (MCK) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs VanEck Vietnam ETF — how do they compare? McKesson Corporation trades at $828.03 (market cap $97.35B), while VanEck Vietnam ETF trades at $16.87. The key difference: McKesson Corporation pays a 0.39% dividend while VanEck Vietnam ETF pays none, and McKesson Corporation is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| MCK | VNM | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Sector/Thematic |
52-Week High | $995.69 | $19.80 |
52-Week Low | $659.01 | $15.35 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
VNM trades at $16.84, down 2.88% on the day, reflecting bearish technical signals with moving averages indicating a downtrend. The stock lacks disclosed valuation ratios, and recent news highlights underperformance relative to other emerging markets. Key support and resistance are tightly clustered around $17, suggesting a critical price zone.
The outlook remains cautious due to technical weakness and emerging market headwinds. Investment opportunities hinge on Vietnam's economic reclassification potential, but risks include power grid strains and geopolitical tensions. Analyst sentiment is mixed, with oscillators showing some bullish divergence amid broader bearish indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
